Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 13/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.49 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10258511 | 1.00 | UCHL1 (0.49) | UCHL1USP30DGAT1TRIM24LMNA | |
| SCHEMBL460677 | 0.92 | DGAT1 (0.56) | UCHL1USP30DGAT1 | |
| SCHEMBL460678 | 0.92 | DGAT1 (0.56) | UCHL1USP30DGAT1 | |
| SCHEMBL460676 | 0.92 | DGAT1 (0.56) | UCHL1USP30DGAT1 | |
| SCHEMBL382918 | 0.90 | DGAT1 (0.54) | UCHL1USP30DGAT1TRIM24 | |
| SCHEMBL382919 | 0.90 | DGAT1 (0.54) | UCHL1USP30DGAT1TRIM24 | |
| SCHEMBL13190608 | 0.88 | UCHL1 (0.55) | UCHL1USP30LMNANPSR1 | |
| SCHEMBL462604 | 0.80 | DGAT1 (0.58) | DGAT1TRIM24 | |
| SCHEMBL462605 | 0.80 | DGAT1 (0.58) | DGAT1TRIM24 | |
| SCHEMBL10261211 | 0.80 | DGAT1 (0.58) | DGAT1TRIM24 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | UCHL1 3297/4885USP30 2841/4885DGAT1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.